Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease
Table 5
Combined genotypes and PON1 activity.
Genotype
CAD patients
Controls
PON1 activity (U/L)
PON1 activity (U/L)
At baseline
After 6 months
After 12 months
At baseline
After 12 months
192QQ/55LL
9
67.77 ± 7.54
66.66 ± 4.79
66 ± 8.21
0.87
8
76.62 ± 10.25
75.75 ± 12.51
0.78
192QQ/55LM
20
68.42 ± 9.51
63.47 ± 9.2¥
69.42 ± 14.94
0.041
14
76.28 ± 15.17
74.78 ± 17.2
0.44
192QQ/55MM
3
55.50 ± 8.69
49 ± 11.12
55 ± 6.24
0.53
10
63.20 ± 12.09
61.60 ± 15.91
0.31
192QR/55LL
4
209.80 ± 38.92
221.14 ± 65.69
239 ± 92.44
0.62
6
190.33 ± 41.26
194.2 ± 56.44
0.5
192QR/55LM
10
191.72 ± 54.12
197.9 ± 61.48
181.62 ± 56.18
0.88
5
184.6 ± 13.01
200.2 ± 28.73
0.5
192QR/55MM
3
192.33 ± 51.73
197.33 ± 48.01
164 ± 60.81
0.13
6
173.66 ± 42.74
187.5 ± 40.25
0.13
192RR/55LL
1
233
238
214
2
288 ± 43.84
306.4 ± 43.84
0.18
192RR/55LM
1
211
266
230
1
265
254
192RR/55MM
2
283.5 ± 58.68
356.5 ± 26.16
352 ± 16.97
0.6
1
414
441
Data is presented as arithmetic means ± SD; ANOVA Friedman test; the Wilcoxon signed-rank test. , after 6 months of treatment compared to the baseline value.
